<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00191100</url>
  </required_header>
  <id_info>
    <org_study_id>4015</org_study_id>
    <secondary_id>B9E-MC-JHQS</secondary_id>
    <nct_id>NCT00191100</nct_id>
  </id_info>
  <brief_title>Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix</brief_title>
  <official_title>Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Mexico: National Institute of Public Health, Health Secretariat</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of two methods of treating cancer
      of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing
      radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will
      receive cisplatin along with radiation therapy without adjuvant therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years</measure>
    <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points</measure>
    <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Failure Rate</measure>
    <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died From Any Cause at Various Time Points</measure>
    <time_frame>baseline to date of death from any cause (includes 60 month follow-up period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points</measure>
    <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Cancer of Cervix</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>LY188011</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Brachytherapy, 30-35 Gy over 1 week</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic radiation</intervention_name>
    <description>Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with cancer of cervix

          -  tumor that can be measured

          -  no previous treatment with chemotherapy or radiation for this cancer

          -  Karnofsky Performance Status Score &gt;=70

          -  able to give written consent

          -  willing and able to participate in the study, both during the active treatment and
             the follow-up period.

        Exclusion Criteria:

          -  impairment such as hearing loss from prior cisplatin therapy

          -  damage to nerves such as being unable to distinguish hot and cold to touch

          -  used other experimental medication in past 30 days

          -  lab test results are not within the limits required for this study

          -  pregnancy or breast-feeding or possibility of becoming pregnant during this study and
             not using an approved method of birth control.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Pakistan</country>
    <country>Peru</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 8, 2009</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>March 30, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine/Cisplatin/Radiation</title>
          <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
        </group>
        <group group_id="P2">
          <title>Cisplatin/Radiation</title>
          <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy, Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy, Stable Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death from Study Drug Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death from Other Cause</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine/Cisplatin/Radiation</title>
          <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
        </group>
        <group group_id="B2">
          <title>Cisplatin/Radiation</title>
          <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="259"/>
                <measurement group_id="B2" value="256"/>
                <measurement group_id="B3" value="515"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.8" spread="9.8"/>
                <measurement group_id="B2" value="46.5" spread="9.2"/>
                <measurement group_id="B3" value="46.1" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="259"/>
                <measurement group_id="B2" value="256"/>
                <measurement group_id="B3" value="515.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Pakistan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="56.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="59.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Argentina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="35.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Thailand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="67.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Peru</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="60.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>India</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="56"/>
                <measurement group_id="B3" value="116.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Bosnia and Herzegovina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="61.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Panama</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="61.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Grade of Histological Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Moderately Differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="114"/>
                <measurement group_id="B2" value="119"/>
                <measurement group_id="B3" value="233.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poorly Differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="92.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="69"/>
                <measurement group_id="B3" value="138.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Undifferentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Well Differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="50.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Scale</title>
          <description>Classifies patients according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Unknown (Missing)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>70 - Unable to carry on normal activity</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>80 - Activity with effort; some signs of disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="17.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>90 - Normal activity; minor signs of disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
                <measurement group_id="B2" value="145"/>
                <measurement group_id="B3" value="292.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>100 - Normal no complaints; no evidence of disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="103"/>
                <measurement group_id="B2" value="101"/>
                <measurement group_id="B3" value="204.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Pathological Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Adenocarcinoma of Cervix</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="32.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Adeno/Squamous Cell Carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="198"/>
                <measurement group_id="B2" value="199"/>
                <measurement group_id="B3" value="397.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other - Poorly Differentiated Carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other - Squamous</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="85.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Western Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="87"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="172.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="62.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>East/Southeast Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="67.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="109"/>
                <measurement group_id="B3" value="214.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Stage of Disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Stage IIIA</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIIB</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="94"/>
                <measurement group_id="B2" value="94"/>
                <measurement group_id="B3" value="188.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIB</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="160"/>
                <measurement group_id="B2" value="156"/>
                <measurement group_id="B3" value="316.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IVA</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="9.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="155.2" spread="6.6"/>
                <measurement group_id="B2" value="154.6" spread="6.7"/>
                <measurement group_id="B3" value="154.9" spread="6.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61.2" spread="11.3"/>
                <measurement group_id="B2" value="62.4" spread="13.0"/>
                <measurement group_id="B3" value="61.8" spread="12.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years</title>
        <description>Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted &quot;Measure Type&quot;, so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.</description>
        <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention-to-treat population includes all randomized participants. Participants were analyzed according to treatment they were randomly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="259"/>
                  <measurement group_id="O2" value="256"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years</title>
            <description>Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted &quot;Measure Type&quot;, so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 Years: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 Years: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.029</p_value>
            <p_value_desc>The p-value is two-sided and was tested at the 0.05 significance level.</p_value_desc>
            <method>Z Statistic</method>
            <param_type>PFS Probability Difference at 3 Years</param_type>
            <param_value>0.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Difference in progression-free survival probability between Gem/Cis/Rad and Cis/Rad. The difference in PFS probability between the two treatment arms can also be presented as a percentage (ie, PFS at 3 years was 9.5% better in the Gem/Cis/Rad arm).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points</title>
        <description>Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.</description>
        <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="259"/>
                  <measurement group_id="O2" value="256"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points</title>
            <description>Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="238"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                  <measurement group_id="O2" value="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0008</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Failure Rate</title>
        <description>Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).</description>
        <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population included all randomized patients with: Histological diagnosis of cancer of cervix; No previous chemotherapy or radiation therapy; Presence of bidimensionally measurable disease, at least 2 cm in diameter; Treatment with at least one dose of study chemotherapy. Patients were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="257"/>
                  <measurement group_id="O2" value="253"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Local Failure Rate</title>
            <description>Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).</description>
            <units>proportion of participants with PD</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.113"/>
                  <measurement group_id="O2" value="0.166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Note: There were 2 patients with unknown site of progressive disease; these patients were counted as a Local failure.
Note: There was 1 patient with both local and distant failure; this patient was counted as a Local failure.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.096</p_value>
            <p_value_desc>The p-value is two-sided and was tested at the 0.05 significance level.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response</title>
        <description>Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.</description>
        <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
        <safety_issue>No</safety_issue>
        <population>Qualified Responders population included all randomized patients with: Histological diagnosis of cancer of cervix; No previous chemotherapy or radiation therapy; Presence of bidimensionally measurable disease, at least 2 cm in diameter; Treatment with at least one dose of study chemotherapy. Patients were analyzed according to treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="256"/>
                  <measurement group_id="O2" value="254"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tumor Response</title>
            <description>Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="223"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.250</p_value>
            <p_value_desc>The p-value is two-sided and was tested at the 0.05 significance level.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died From Any Cause at Various Time Points</title>
        <description>Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.</description>
        <time_frame>baseline to date of death from any cause (includes 60 month follow-up period)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="259"/>
                  <measurement group_id="O2" value="256"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Died From Any Cause at Various Time Points</title>
            <description>Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="253"/>
                  <measurement group_id="O2" value="254"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="248"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="222"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="207"/>
                  <measurement group_id="O2" value="195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="182"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="175"/>
                  <measurement group_id="O2" value="158"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0224</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points</title>
        <description>Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.</description>
        <time_frame>Tumor assessments at baseline, weekly during chemoradiation &amp; brachytherapy, on Day 1 of adjuvant Cycles 1&amp;2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population includes all randomized patients. Patients were analyzed according to treatment they were randomly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Cisplatin/Radiation</title>
            <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin/Radiation</title>
            <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="259"/>
                  <measurement group_id="O2" value="256"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points</title>
            <description>Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="238"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                  <measurement group_id="O2" value="195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>18 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                  <measurement group_id="O2" value="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients with Event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>36 Months: Number of Patients at Risk</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0227</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine/Cisplatin/Radiation</title>
          <description>Gemcitabine: 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week
Two week rest period with no chemotherapy or radiation
Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles</description>
        </group>
        <group group_id="E2">
          <title>Cisplatin/Radiation</title>
          <description>Cisplatin: 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks Pelvic radiation: 1.8 Gy/day, 5 days/week, 6 weeks
Brachytherapy, 30-35 Gy over 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44"/>
                <counts group_id="E2" subjects_affected="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259"/>
                <counts group_id="E2" subjects_affected="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="233" subjects_affected="175" subjects_at_risk="260"/>
                <counts group_id="E2" events="130" subjects_affected="115" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="271" subjects_affected="145" subjects_at_risk="260"/>
                <counts group_id="E2" events="124" subjects_affected="114" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="260"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="378" subjects_affected="193" subjects_at_risk="260"/>
                <counts group_id="E2" events="78" subjects_affected="74" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="66" subjects_at_risk="260"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="115" subjects_affected="87" subjects_at_risk="260"/>
                <counts group_id="E2" events="64" subjects_affected="57" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="260"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="207" subjects_affected="159" subjects_at_risk="260"/>
                <counts group_id="E2" events="151" subjects_affected="131" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="280" subjects_affected="167" subjects_at_risk="260"/>
                <counts group_id="E2" events="179" subjects_affected="155" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="260"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="248" subjects_affected="146" subjects_at_risk="260"/>
                <counts group_id="E2" events="138" subjects_affected="121" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="260"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="126" subjects_affected="80" subjects_at_risk="260"/>
                <counts group_id="E2" events="67" subjects_affected="57" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="31" subjects_at_risk="260"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="260"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="77" subjects_affected="72" subjects_at_risk="260"/>
                <counts group_id="E2" events="67" subjects_affected="65" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="81" subjects_affected="62" subjects_at_risk="260"/>
                <counts group_id="E2" events="59" subjects_affected="51" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="53" subjects_at_risk="260"/>
                <counts group_id="E2" events="46" subjects_affected="44" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="260"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="260"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="114" subjects_affected="95" subjects_at_risk="260"/>
                <counts group_id="E2" events="85" subjects_affected="80" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="260"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital discharge</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="80" subjects_affected="71" subjects_at_risk="260"/>
                <counts group_id="E2" events="68" subjects_affected="63" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="84" subjects_affected="70" subjects_at_risk="260"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="157" subjects_affected="148" subjects_at_risk="260"/>
                <counts group_id="E2" events="162" subjects_affected="157" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="260"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="260"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
